دورية أكاديمية
Dupilumab therapy of atopic dermatitis of the elderly. A multi-centre, real-life study
| العنوان: | Dupilumab therapy of atopic dermatitis of the elderly. A multi-centre, real-life study |
|---|---|
| المؤلفون: | C Patruno, M Napolitano, G Argenziano, K Peris, M Ortoncelli, G Girolomoni, A Offidani, S M Ferrucci, G F Amoruso, M Rossi, L Stingeni, G Malara, T Grieco, C Foti, M Gattoni, C Loi, M Iannone, M Talamonti, G Stinco, F Rongioletti, P D Pigatto, A Cristaudo, E Nettis, M Corazza, F Guarneri, P Amerio, M Esposito, A Belloni Fortina, C Potenza, G Fabbrocini, DADE - Dupilumab for Atopic Dermatitis of the Elderly study group |
| المساهمون: | Patruno, C, Napolitano, M, Argenziano, G, Peris, K, Ortoncelli, M, Girolomoni, G, Offidani, A, M Ferrucci, S, F Amoruso, G, Rossi, M, Stingeni, L, Malara, G, Grieco, T, Foti, C, Gattoni, M, Loi, C, Iannone, M, Talamonti, M, Stinco, G, Rongioletti, F, D Pigatto, P, Cristaudo, A, Nettis, E, Corazza, M, Guarneri, F, Amerio, P, Esposito, M, Belloni Fortina, A, Potenza, C, Fabbrocini, G, Dupilumab for Atopic Dermatitis of the Elderly study group, Dade |
| سنة النشر: | 2020 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: | atopic dermatiti, dupilumab, elderly |
| الوصف: | Background: Treatment of moderate-to-severe atopic dermatitis in the elderly may be challenging, due to side effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab is not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥ 65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS, and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis, The coexistence of more than 1 phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/33332697; info:eu-repo/semantics/altIdentifier/wos/WOS:000608704000001; firstpage:1; lastpage:7; numberofpages:7; journal:JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY; http://hdl.handle.net/11573/1475104Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85099666117 |
| DOI: | 10.1111/jdv.17094 |
| الإتاحة: | https://doi.org/10.1111/jdv.17094Test http://hdl.handle.net/11573/1475104Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.DA4C033A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/jdv.17094 |
|---|